Avacta doses first patient in chemotherapy medication trial
Avacta doses first patient in chemotherapy medication trial
Read moreWed, 23rd Dec 2020 08:56
Avacta doses first patient in chemotherapy medication trial
Read more(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that the first patient has been dosed in its phase 1 multicentre trial evaluating 'AVA6000', which it described as a "novel pro-drug" of 'doxorubicin', and its first therapeutic product based on the proprietary 'preCISION' technology.
Read moreIN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts
Read moreAIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down
Read moreIN BRIEF: Avacta wins manufacturer certification for lateral flow test
Read more(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced on Wednesday that its life sciences diagnostics division has achieved ISO 13485 certification on the quality management system for the manufacture and distribution of 'Affimer' reagents, for use in lateral flow, ELISA and immunodiagnostic in-vitro diagnostic devices.
Read moreIN BRIEF: Avacta's lateral flow test detects Covid Delta variant
Read moreAIM WINNERS & LOSERS: Avacta virus test works; React virus boost ebbs
Read more(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group announced on Tuesday that a study has shown that its 'AffiDX' antigen lateral flow test detects the 'Delta' variant of the SARS-CoV-2 virus in clinical samples.
Read moreAIM WINNERS & LOSERS: Mercantile Ports jumps on pact; Avacta recovers
Read moreIN BRIEF: Avacta signs distribution deal for its Covid test
Read moreUK shareholder meetings calendar - next 7 days
Read more(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has entered into a non-exclusive distribution agreement with life science products company Calibre Scientific, it announced on Monday, for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use in the UK and the European Economic Area (EEA).
Read more(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has received notice of registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test in the European Union, allowing it to place the product on the market for professional use in all 27 countries of the EU.
Read moreAvacta Covid lateral flow test gets regulatory green light in EU
Read more